The US Food and Drug Administration (FDA) has approved Glatopa (Sandoz), 40 mg/mL injection, a generic version of the multiple sclerosis (MS) drug glatiramer acetate (Copaxone, Teva Pharmaceuticals).
The product is a fully substitutable, AP-rated generic version of Copaxone 40 mg/mL, three times weekly for relapsing forms of MS, Sandoz said in a news release.
Glatopa 40 mg/mL joins Glatopa 20 mg/mL, which was approved in the United States in 2015.
Sandoz GlatopaCare offers a $0 copay support program to qualified patients. The company also offers patients personalized injection training, 24-hour access to nurses for product-related questions, and a free starter kit, which includes the Glatopaject injection device, designed to work with both the 20-mg/mL and 40-mg/mL prefilled syringes.
Full prescribing information for the product is available online.
For more Medscape Neurology news, join us on Facebook and Twitter
Tidak ada komentar:
Posting Komentar